Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery

Article metrics


Bariatric surgery is currently the most effective therapy for type 2 diabetes. However, the mechanisms underlying its beneficial effects remain elusive. Here we studied the effects of bariatric surgery on circulating meteorin-like (Metrnl) and oncostatin m (OSM) levels, two hormones intimately linked to energy homeostasis. Metrnl and OSM levels were assessed at baseline, 6 and 12 months after laparoscopic sleeve gastrectomy (LSG) in 25 patients with obesity, as well as in 33 normal-weight controls. At baseline, patients with obesity showed lower Metrnl and higher OSM levels compared to controls. LSG increased Metrnl and decreased OSM levels, in correlation to improvements in glucose and lipid homeostasis. Our data indicate that LSG conversely modulated Metrnl and OSM levels, and suggest that a dual approach modulating these two molecules might provide a novel strategy for obesity and type 2 diabetes treatment.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. 1

    Aron-Wisnewsky J, Tordjman J, Poitou C, Darakhshan F, Hugol D, Basdevant A et al. Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab 2009; 94: 4619–4623.

  2. 2

    Pontiroli AE, Morabito A . Long-term prevention of mortality in morbid obesity through bariatric surgery: a systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg 2011; 253: 484–487.

  3. 3

    Poitou C, Perret C, Mathieu F, Truong V, Blum Y, Durand H et al. Bariatric surgery induces disruption in inflammatory signaling pathways mediated by immune cells in adipose tissue: a RNA-Seq study. PLoS One 2015; 10: e0125718.

  4. 4

    Cummings DE, Cohen RV . Bariatric/metabolic surgery to treat type 2 diabetes in patients with a BMI <35 kg/m2. Diabetes Care 2016; 39: 924–933.

  5. 5

    Vijgen GH, Bouvy ND, Teule GJ, Brans B, Hoeks J, Schrauwen P et al. Increase in brown adipose tissue activity after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 2012; 97: E1229–E1233.

  6. 6

    Rachid B, van de Sande-Lee S, Rodovalho S, Folli F, Beltramini GC, Morari J et al. Distinct regulation of hypothalamic and brown/beige adipose tissue activities in human obesity. Int J Obes (Lond) 2015; 39: 1515–1522.

  7. 7

    Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell 2014; 5: 1279–1291.

  8. 8

    Sánchez-Infantes D, Cereijo R, Peyrou M, Piquer-Garcia I, Stephens JM, Villarroya F . Oncostatin m impairs brown adipose tissue thermogenic function and the browning of subcutaneous white adipose tissue. Obesity (Silver Spring) 2017; 25: 85–93.

  9. 9

    Sanchez-Infantes D, White UA, Elks CM, Morrison RF, Gimble JM, Considine RV et al. Oncostatin m is produced in adipose tissue and is regulated in conditions of obesity and type 2 diabetes. J Clin Endocrinol Metab 2014; 99: E217–E225.

  10. 10

    Li ZY, Song J, Zheng SL, Fan MB, Guan YF, Qu Y et al. Adipocyte Metrnl antagonizes insulin resistance through PPARγ signaling. Diabetes 2015; 64: 4011–4022.

  11. 11

    Albiero M, Poncina N, Ciciliot S, Cappellari R, Menegazzo L, Ferraro F et al. Bone marrow macrophages contribute to diabetic stem cell mobilopathy by producing oncostatin M. Diabetes 2015; 64: 2957–2968.

  12. 12

    West NR, Hegazy AN, Owens BM, Bullers SJ, Linggi B, Buonocore S et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 2017; 23: 579–589.

Download references


Samples from patients included in this study were provided by the IGTP HUGTP Biobank integrated in the Spanish National Biobanks Network of Instituto de Salud Carlos III (PT13/0010/0009) and they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committees. DS-I is an Investigator of the Miguel Servet Fund from Carlos III National Institute of Health, Spain. AP is a Ramón y Cajal researcher. This study was supported by Instituto de Salud Carlos III, and by the Fondo Europeo de Desarrollo Regional (FEDER), Madrid, Spain (CP15/00106), and by SAF2014-55702-JIN from the Ministerio de Ciencia e Innovación, Spain, co-financed by the European Regional Development Fund (ERDF).

Author information

Correspondence to A Planavila or D Sánchez-Infantes.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on International Journal of Obesity website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading